Evidence map›Paper›PMID 36232810›Full record

ArticleInternational journal of molecular sciences2022

Role of m6A RNA Methylation in Thyroid Cancer Cell Lines.

Lorenzo Allegri, Federica Baldan, Elisabetta Molteni, Catia Mio, Giuseppe Damante

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lorenzo AllegriDepartment of Medicine, University of Udine, Via Chiusaforte, 33100 Udine, Italy.
Federica BaldanInstitute of Medical Genetics, Academic Hospital of Udine, Azienda Sanitaria Universitaria Integrata di Udine, 33100 Udine, Italy.ORCID 0000-0003-1164-1316
Elisabetta MolteniDepartment of Medicine, University of Udine, Via Chiusaforte, 33100 Udine, Italy.
Catia MioDepartment of Medicine, University of Udine, Via Chiusaforte, 33100 Udine, Italy.ORCID 0000-0002-6245-8266
Giuseppe DamanteDepartment of Medicine, University of Udine, Via Chiusaforte, 33100 Udine, Italy.
University of Udine · ITOspedale Santa Maria della Misericordia di Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N6-methyladenosine (m6A) is the most abundant internal modification of RNA in eukaryotic cells, and, in recent years, it has gained increasing attention. A good amount of data support the involvement of m6A modification in tumorigenesis, tumor progression, and metastatic dissemination. However, the role of this RNA modification in thyroid cancer still remains poorly investigated. In this study, m6A-related RNA methylation profiles are compared between a normal thyroid cell line and different thyroid cancer cell lines. With this approach, it was possible to identify the different patterns of m6A modification in different thyroid cancer models. Furthermore, by silencing METTL3, which is the main player in the RNA methylation machinery, it was possible to evaluate the impact of m6A modification on gene expression in an anaplastic thyroid cancer model. This experimental approach allowed us to identify

Indexed as

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsCell LineHumansMethylationMethyltransferasesRNAMethyltransferasesMETTL3 protein, humanRNAepitranscriptomem6AMETTL3RNA methylationthyroid cancer

Identifiers

PMID36232810
PMCPMC9569446
OpenAlexW4297982609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.